DNLI Jun 2024 25.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:36AM EDT. Market open.
Loading interactive chart…
- GlobeNewswire
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseasesDNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potential for clinical benefit for a rare neurodegenerative disease and the drug sponsor’s ability to advance development towards a marketing application Participation in START is expected to facilitate and accelerate de
- Simply Wall St.
The Consensus EPS Estimates For Denali Therapeutics Inc. (NASDAQ:DNLI) Just Fell Dramatically
The latest analyst coverage could presage a bad day for Denali Therapeutics Inc. ( NASDAQ:DNLI ), with the analysts...
- Simply Wall St.
Denali Therapeutics First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)
Denali Therapeutics ( NASDAQ:DNLI ) First Quarter 2024 Results Key Financial Results Net loss: US$101.8m (loss narrowed...
© 2024 Yahoo. All rights reserved.